Table 2.
Number of genes and variants and significance level of the five significant inflammation-related subpathways*
| Cancer type | Inflammation- related cell cycle | Inflammatory response | Immune system development | Activation of immune response | Innate immune response |
|---|---|---|---|---|---|
| No. genes (no. variants) | 14 (37) | 83 (975) | 324 (4910) | 90 (1306) | 197 (2411) |
| No. genes (No. variants) - After LD pruning at R2 of 0.7 | 11 (22) | 66 (410) | 302 (1979) | 85 (528) | 173 (925) |
| Overall P | 1.23x10-4 | .008 | .025 | .028 | .030 |
| Lung cancer P | 1.35x10-6 | .952 | .239 | .068 | .054 |
| Colorectal cancer P | .333 | .006 | .518 | .973 | .022 |
| Ovary cancer P | .121 | .594 | .265 | .009 | .003 |
| Breast cancer P | .902 | .058 | .001 | .114 | .302 |
| Prostate cancer P | .810 | .941 | .566 | .587 | .194 |
* The pathway significance levels were estimated based on the hierarchical modeling based on the method previously described in Chen et al. (18). LD = linkage disequilibrium.